The State Department of Public Health of Rio Grande do Norte (Sesap) temporarily suspended the application of the Butantan-DV vaccine against dengue. The measure follows guidance from the Ministry of Health. In Rio Grande do Norte there was no notification of a reaction to this immunizer. The campaign with the Qdenga vaccine, aimed at children and adolescents aged 10 to 14, continues normally in the state. The suspension comes after the Ministry of Health identified 42 severe cases under investigation and two deaths under analysis in the country. The cases may be related to the vaccine produced by the Butantan Institute. Among the adverse symptoms recorded are the simulation of dengue and, in severe situations, the occurrence of hemorrhages. There is still no conclusive result on the correlation of symptoms with the vaccine. Dengue vaccine Butantan Institute/ Disclosure According to Sesap's Health Surveillance coordinator, Diana Rego, the Ministry acted diligently, identifying 42 severe cases under investigation and two deaths that are being analyzed for causality, and could be related to the vaccine produced by Butantan. In Brazil, notifications considered serious correspond to 0.008% of a total of 500 thousand doses applied until May 30th. Sesap emphasizes that monitoring is part of pharmacovigilance. All doses of new vaccines are monitored and any suspicion of risk requires suspension for investigation. In Rio Grande do Norte, there was no notification of a reaction to Butantan-DV. Vaccination with this vaccine began in January, aimed at Primary Care workers. The state applied 5,200 of the 18,520 doses received. Immunization with the Qdenga vaccine is ongoing. The immunizer recorded allergic reactions, with 108 reports of adverse reactions recorded, only two of which were considered serious.